Kitov Pharmaceuticals Stock Price, News & Analysis (NASDAQ:KTOV)

$2.59 +0.10 (+4.02 %)
(As of 02/22/2018 08:00 AM ET)
Previous Close$2.59
Today's Range$2.46 - $2.74
52-Week Range$1.27 - $3.44
Volume191,700 shs
Average Volume152,486 shs
Market Capitalization$29.03 million
P/E RatioN/A
Dividend YieldN/A
Beta3.21

About Kitov Pharmaceuticals (NASDAQ:KTOV)

Kitov Pharmaceuticals logoKitov Pharma Ltd, formerly Kitov Pharmaceuticals Holdings Ltd, is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.

Receive KTOV News and Ratings via Email

Sign-up to receive the latest news and ratings for KTOV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KTOV
CUSIPN/A
Phone972-3933-3121

Debt

Debt-to-Equity RatioN/A
Current Ratio7.60%
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.43 per share
Price / Book0.76

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees9
Outstanding Shares11,210,000

Kitov Pharmaceuticals (NASDAQ:KTOV) Frequently Asked Questions

What is Kitov Pharmaceuticals' stock symbol?

Kitov Pharmaceuticals trades on the NASDAQ under the ticker symbol "KTOV."

When will Kitov Pharmaceuticals make its next earnings announcement?

Kitov Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Kitov Pharmaceuticals.

Where is Kitov Pharmaceuticals' stock going? Where will Kitov Pharmaceuticals' stock price be in 2018?

1 brokers have issued twelve-month price objectives for Kitov Pharmaceuticals' stock. Their predictions range from $10.00 to $10.00. On average, they expect Kitov Pharmaceuticals' stock price to reach $10.00 in the next twelve months. View Analyst Ratings for Kitov Pharmaceuticals.

Who are some of Kitov Pharmaceuticals' key competitors?

Who are Kitov Pharmaceuticals' key executives?

Kitov Pharmaceuticals' management team includes the folowing people:

  • John Paul Waymack, Chairman of the Board & Chief Medical Officer (Age 63)
  • Itzhak Israel, Chief Executive Officer, Director (Age 37)
  • Simcha Rock, Chief Financial Officer, Director (Age 65)
  • Gil Ben-Menachem, Vice President - Business Development
  • Yisrael Gewirtz, Internal Auditor (Age 40)
  • Ido Agmon, Director (Age 39)
  • Steven Steinberg, Director (Age 55)
  • Arie Weber, Director (Age 68)
  • Alain Zeitoun, External Director (Age 55)
  • Philip Adam Serlin, Independent Director (Age 57)

When did Kitov Pharmaceuticals IPO?

(KTOV) raised $13 million in an initial public offering (IPO) on Friday, November 20th 2015. The company issued 3,200,000 shares at a price of $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar acted as the underwriters for the IPO.

How do I buy Kitov Pharmaceuticals stock?

Shares of Kitov Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kitov Pharmaceuticals' stock price today?

One share of Kitov Pharmaceuticals stock can currently be purchased for approximately $2.59.

How big of a company is Kitov Pharmaceuticals?

Kitov Pharmaceuticals has a market capitalization of $29.03 million. Kitov Pharmaceuticals employs 9 workers across the globe.

How can I contact Kitov Pharmaceuticals?

Kitov Pharmaceuticals' mailing address is One Azrieli Center 132 Menachem Begin Road, Tel Aviv L3, 6701101. The company can be reached via phone at 972-3933-3121.


MarketBeat Community Rating for Kitov Pharmaceuticals (KTOV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  45 (Vote Underperform)
Total Votes:  110
MarketBeat's community ratings are surveys of what our community members think about Kitov Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Kitov Pharmaceuticals (NASDAQ:KTOV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$10.00$10.00N/A
Price Target Upside: 407.61% upside407.61% upside407.61% upsideN/A

Kitov Pharmaceuticals (NASDAQ:KTOV) Consensus Price Target History

Price Target History for Kitov Pharmaceuticals (NASDAQ:KTOV)

Kitov Pharmaceuticals (NASDAQ:KTOV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017HC WainwrightUpgradeNeutral -> Buy$10.00N/AView Rating Details
7/11/2016Rodman & RenshawReiterated RatingBuyN/AView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Earnings History for Kitov Pharmaceuticals (NASDAQ:KTOV)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Kitov Pharmaceuticals (NASDAQ:KTOV) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.05 EPS
Next Year EPS Consensus Estimate: $-0.01 EPS

Dividends

Dividend History for Kitov Pharmaceuticals (NASDAQ:KTOV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Kitov Pharmaceuticals (NASDAQ KTOV)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Kitov Pharmaceuticals (NASDAQ KTOV) News Headlines

Source:
DateHeadline
Analysts Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) to Post ($0.01) Earnings Per ShareAnalysts Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) to Post ($0.01) Earnings Per Share
www.americanbankingnews.com - February 19 at 1:16 AM
 Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) Will Announce Earnings of -$0.01 Per Share Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) Will Announce Earnings of -$0.01 Per Share
www.americanbankingnews.com - February 15 at 3:16 AM
Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given Average Rating of "Strong Buy" by BrokeragesZacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 30 at 1:20 PM
Zacks: Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) to Announce -$0.01 EPSZacks: Brokerages Anticipate Kitov Pharmaceuticals Holdings Ltd (KTOV) to Announce -$0.01 EPS
www.americanbankingnews.com - January 29 at 5:12 AM
Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Receives Average Recommendation of "Strong Buy" from BrokeragesZacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - January 22 at 5:18 AM
-$0.01 EPS Expected for Kitov Pharmaceuticals Holdings Ltd (KTOV) This Quarter-$0.01 EPS Expected for Kitov Pharmaceuticals Holdings Ltd (KTOV) This Quarter
www.americanbankingnews.com - January 12 at 8:02 AM
Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given Consensus Rating of "Strong Buy" by BrokeragesZacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 5 at 7:12 PM
Zacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given $10.00 Average Target Price by BrokeragesZacks: Kitov Pharmaceuticals Holdings Ltd (KTOV) Given $10.00 Average Target Price by Brokerages
www.americanbankingnews.com - December 16 at 9:56 AM
Kitov Announces Consensi™ as Brand Name for KIT-302Kitov Announces Consensi™ as Brand Name for KIT-302
finance.yahoo.com - December 14 at 6:06 PM
Kitov Pharmaceuticals (KTOV) & Edge Therapeutics (EDGE) Head-To-Head SurveyKitov Pharmaceuticals (KTOV) & Edge Therapeutics (EDGE) Head-To-Head Survey
www.americanbankingnews.com - December 12 at 7:57 AM
 Analysts Set $10.00 Target Price for Kitov Pharmaceuticals Holdings Ltd. (KTOV) Analysts Set $10.00 Target Price for Kitov Pharmaceuticals Holdings Ltd. (KTOV)
www.americanbankingnews.com - November 25 at 3:24 AM
Kitov Pharmaceuticals Holdings Ltd. (KTOV) Stock Rating Upgraded by HC WainwrightKitov Pharmaceuticals Holdings Ltd. (KTOV) Stock Rating Upgraded by HC Wainwright
www.americanbankingnews.com - November 21 at 4:41 PM
Kitov Pharmaceuticals Holdings (KTOV) versus Aurinia Pharmaceuticals (AUPH) Head to Head ReviewKitov Pharmaceuticals Holdings (KTOV) versus Aurinia Pharmaceuticals (AUPH) Head to Head Review
www.americanbankingnews.com - November 6 at 1:33 PM
BRIEF-Kitov pharmaceuticals announces receipt of FDAs favorable response to NT219s pre-ind meeting packageBRIEF-Kitov pharmaceuticals announces receipt of FDA's favorable response to NT219's pre-ind meeting package
www.reuters.com - November 3 at 6:50 PM
Kitov Pharmaceuticals Announces Receipt of FDAs Favorable Response to NT219s pre-IND Meeting PackageKitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package
finance.yahoo.com - November 2 at 4:47 AM
Kitov Pharmaceuticals: An UpdateKitov Pharmaceuticals: An Update
seekingalpha.com - November 1 at 5:06 AM
Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal FunctionKitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function
finance.yahoo.com - October 26 at 4:48 PM
BRIEF-Kitov boosts ownership in Tyrnovo and Oncology platformBRIEF-Kitov boosts ownership in Tyrnovo and Oncology platform
www.reuters.com - October 7 at 2:08 AM
Kitov ups stake in oncology-focused TyrNovo to 92%; shares ahead 9% premarketKitov ups stake in oncology-focused TyrNovo to 92%; shares ahead 9% premarket
seekingalpha.com - October 7 at 2:08 AM
Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for StockKitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock
finance.yahoo.com - October 7 at 2:08 AM
Pro-Trader Daily: Corporate News Blog - US FDA Accepts Kitov Pharmas Lead Drug Candidate for Full ReviewPro-Trader Daily: Corporate News Blog - US FDA Accepts Kitov Pharma's Lead Drug Candidate for Full Review
www.finanznachrichten.de - October 5 at 7:37 AM
Corporate News Blog - US FDA Accepts Kitov Pharma’s Lead Drug Candidate for Full ReviewCorporate News Blog - US FDA Accepts Kitov Pharma’s Lead Drug Candidate for Full Review
finance.yahoo.com - October 5 at 7:37 AM
Kitov Pharma (KTOV) Reports FDA Filing for New Drug Application for KIT-302Kitov Pharma (KTOV) Reports FDA Filing for New Drug Application for KIT-302
www.streetinsider.com - October 2 at 12:32 PM
Kitov files U.S. marketing application for lead candidate KIT-302; shares ahead 8% premarketKitov files U.S. marketing application for lead candidate KIT-302; shares ahead 8% premarket
seekingalpha.com - October 2 at 12:32 PM
Kitov Announces Filing by FDA of New Drug Application for KIT-302Kitov Announces Filing by FDA of New Drug Application for KIT-302
finance.yahoo.com - October 2 at 12:32 PM
Kitov Pharmaceuticals Holdings Ltd. (KTOV) Expected to Announce Earnings of -$0.16 Per ShareKitov Pharmaceuticals Holdings Ltd. (KTOV) Expected to Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - August 17 at 6:16 PM
Kitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial ResultsKitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial Results
finance.yahoo.com - August 16 at 8:30 PM
Kitov submits U.S. marketing application for lead candidate KIT-302; shares down 3%Kitov submits U.S. marketing application for lead candidate KIT-302; shares down 3%
seekingalpha.com - August 1 at 12:44 AM
Kitov Submits New Drug Application to FDA for KIT-302Kitov Submits New Drug Application to FDA for KIT-302
finance.yahoo.com - July 31 at 7:42 PM
Kitov Pharmaceuticals Holdings Ltd. (NASDAQ:KTOV) Expected to Announce Earnings of -$0.16 Per ShareKitov Pharmaceuticals Holdings Ltd. (NASDAQ:KTOV) Expected to Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - July 30 at 2:09 PM
Kitov Pharma (KTOV) Announces Results Showing NT-219 Enhanced Efficacy of Keytruda in Immune-Oncology Preclinical ModelKitov Pharma (KTOV) Announces Results Showing NT-219 Enhanced Efficacy of Keytruda in Immune-Oncology Preclinical Model
www.streetinsider.com - July 18 at 9:32 PM
Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical ModelKitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model
finance.yahoo.com - July 18 at 4:29 PM
Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct OfferingKitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering
finance.yahoo.com - July 12 at 2:04 AM
Kitov Pharmaceuticals Says on July 6 Named Gil Ben-Menachem to Fill Vacancy on BoardKitov Pharmaceuticals Says on July 6 Named Gil Ben-Menachem to Fill Vacancy on Board
finance.yahoo.com - July 8 at 12:10 PM
Kitov Pharmaceuticals Holdings (KTOV) Has Surged To A 4-Month HighKitov Pharmaceuticals Holdings (KTOV) Has Surged To A 4-Month High
www.rttnews.com - July 7 at 6:54 AM
-$0.16 EPS Expected for Kitov Pharmaceuticals Holdings Ltd. (KTOV) This Quarter-$0.16 EPS Expected for Kitov Pharmaceuticals Holdings Ltd. (KTOV) This Quarter
www.americanbankingnews.com - July 6 at 10:30 AM
Kitov Pharma (KTOV) Provides Update on KIT-302 New Drug ApplicationKitov Pharma (KTOV) Provides Update on KIT-302 New Drug Application
www.streetinsider.com - June 27 at 1:07 AM
BRIEF-Kitov Pharmaceuticals discloses additional details of Israeli Securities Authority investigationBRIEF-Kitov Pharmaceuticals discloses additional details of Israeli Securities Authority investigation
www.reuters.com - May 1 at 5:17 PM
U.S. Food and Drug Administration Grants Kitov a Waiver for New Drug Application Filing FeeU.S. Food and Drug Administration Grants Kitov a Waiver for New Drug Application Filing Fee
www.bizjournals.com - April 4 at 6:44 AM
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with  Losses on their Investment in Kitov Pharmaceuticals Holdings Ltd. of  Class Action Lawsuit and Upcoming Deadline – KTOVSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kitov Pharmaceuticals Holdings Ltd. of Class Action Lawsuit and Upcoming Deadline – KTOV
feeds.benzinga.com - March 31 at 8:31 PM
SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals ... - Business Wire (press release)SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals ... - Business Wire (press release)
www.businesswire.com - March 28 at 10:53 AM
9:00 am Kitov Pharmaceuticals will discuss recent promising results demonstrating NT219s efficacy in patient-derived xenograft models in mice at the AACR Annual Meeting on April 39:00 am Kitov Pharmaceuticals will discuss recent 'promising results demonstrating NT219's efficacy in patient-derived xenograft models in mice' at the AACR Annual Meeting on April 3
us.rd.yahoo.com - March 27 at 5:44 PM
Kitov Pharmas (KTOV) TyrNovo to Present Preclinical Data at AACRKitov Pharma's (KTOV) TyrNovo to Present Preclinical Data at AACR
www.streetinsider.com - March 27 at 10:41 AM
Lifshitz & Miller LLP Announces Investigation of Cemtrex, Inc., Kitov Pharmaceuticals Holdings LTD, NantHealth, Inc ... - PR Newswire (press release)Lifshitz & Miller LLP Announces Investigation of Cemtrex, Inc., Kitov Pharmaceuticals Holdings LTD, NantHealth, Inc ... - PR Newswire (press release)
www.prnewswire.com - March 26 at 5:47 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Kitov Pharmaceutical Holdings LTD (KTOV) & Lead Plaintiff Deadline - April 10, 2017SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Kitov Pharmaceutical Holdings LTD (KTOV) & Lead Plaintiff Deadline - April 10, 2017
us.rd.yahoo.com - March 16 at 7:01 PM
DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Kitov ...DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Kitov ...
www.businesswire.com - March 14 at 11:51 PM
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Kitov Pharmaceutical Holdings LTD (KTOV) and Lead Plaintiff Deadline: April 10, 2017SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Kitov Pharmaceutical Holdings LTD (KTOV) and Lead Plaintiff Deadline: April 10, 2017
us.rd.yahoo.com - March 10 at 7:27 PM
Cohen Milstein Sellers & Toll PLLC Announces Investigation of Kitov Pharmaceuticals Holdings Ltd.Cohen Milstein Sellers & Toll PLLC Announces Investigation of Kitov Pharmaceuticals Holdings Ltd.
us.rd.yahoo.com - March 10 at 7:27 PM
BRIEF-Kitov Pharmaceuticals says signed a license agreement for KIT-302BRIEF-Kitov Pharmaceuticals says signed a license agreement for KIT-302
www.reuters.com - March 8 at 6:59 PM
Kitov Pharma out-licenses lead product candidate KIT-302 in South Korea; shares ahead 13%Kitov Pharma out-licenses lead product candidate KIT-302 in South Korea; shares ahead 13%
seekingalpha.com - March 8 at 6:59 PM

SEC Filings

Kitov Pharmaceuticals (NASDAQ:KTOV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Kitov Pharmaceuticals (NASDAQ:KTOV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Kitov Pharmaceuticals (NASDAQ KTOV) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.